- Home
- BCIC vs CGTX Comparison
BCIC vs CGTX Comparison
Compare BCIC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCIC
- CGTX
- Stock Information
- Founded
- BCIC 2006
- CGTX 2007
- Country
- BCIC United States
- CGTX United States
- Employees
- BCIC N/A
- CGTX N/A
- Industry
- BCIC Finance: Consumer Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCIC Finance
- CGTX Health Care
- Exchange
- BCIC Nasdaq
- CGTX Nasdaq
- Market Cap
- BCIC 159.5M
- CGTX 158.8M
- IPO Year
- BCIC N/A
- CGTX 2021
- Fundamental
- Price
- BCIC $11.65
- CGTX $1.68
- Analyst Decision
- BCIC
- CGTX Strong Buy
- Analyst Count
- BCIC 0
- CGTX 3
- Target Price
- BCIC N/A
- CGTX $2.83
- AVG Volume (30 Days)
- BCIC 49.5K
- CGTX 1.9M
- Earning Date
- BCIC 11-06-2025
- CGTX 11-12-2025
- Dividend Yield
- BCIC 16.90%
- CGTX N/A
- EPS Growth
- BCIC N/A
- CGTX N/A
- EPS
- BCIC N/A
- CGTX N/A
- Revenue
- BCIC $54,317,000.00
- CGTX N/A
- Revenue This Year
- BCIC N/A
- CGTX N/A
- Revenue Next Year
- BCIC $14.84
- CGTX N/A
- P/E Ratio
- BCIC N/A
- CGTX N/A
- Revenue Growth
- BCIC N/A
- CGTX N/A
- 52 Week Low
- BCIC $11.12
- CGTX $0.22
- 52 Week High
- BCIC $18.92
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- BCIC N/A
- CGTX 49.04
- Support Level
- BCIC N/A
- CGTX $1.59
- Resistance Level
- BCIC N/A
- CGTX $1.78
- Average True Range (ATR)
- BCIC 0.00
- CGTX 0.16
- MACD
- BCIC 0.00
- CGTX -0.01
- Stochastic Oscillator
- BCIC 0.00
- CGTX 19.57
About BCIC BCP Investment Corporation Common Stock
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.